香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：383） 截至二零二二年十二月三十一日止之年度業績公告 中國醫療網絡有限公司（「本公司」）之董事會（分別為「董事」及「董事會」）謹此宣佈， 本公司及其附屬公司（統稱為「本集團」）截至二零二二年十二月三十一日止年度之 經審核綜合業績連同截至二零二一年十二月三十一日止年度之比較數字如下： 綜合損益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 3 1,437,863 1,463,495 出售持作買賣之投資所得款項總額 — 2,184 總額 1,437,863 1,465,679 ...

Financial Performance - The total revenue for the six months ended June 30, 2022, was HKD 736,020, an increase of 3.6% compared to HKD 710,856 for the same period in 2021[2]. - The gross profit for the period was HKD 117,467, down from HKD 136,563 in the previous year, reflecting a decrease of approximately 14%[2]. - The net loss for the six months ended June 30, 2022, was HKD 39,810, a significant improvement compared to a net loss of HKD 65,779 in the same period of 2021, representing a reduction of about 39.4%[2]. - The basic loss per share for the period was HKD 0.30, compared to HKD 0.51 for the same period last year[4]. - The total comprehensive loss for the period was HKD 64,389, compared to HKD 57,498 in the previous year, indicating an increase in losses[6]. - Cash generated from operating activities was HKD 23,801,000, a significant decrease from HKD 81,675,000 in the prior year[14]. - The company experienced a net cash outflow from operating activities of HKD 8,391,000, compared to a net inflow of HKD 41,763,000 in the previous year[14]. - The company reported a significant foreign exchange loss of HKD 24,505 during the period, compared to a gain of HKD 8,196 in the previous year[6]. - The company reported a net loss of HKD 39,810,000 for the six months ended June 30, 2022[19]. - The loss attributable to the company's owners for the same period was HKD 43,902,000, a decrease of approximately 40.6% from HKD 73,899,000 in the first half of 2021[99]. Revenue Breakdown - Revenue from hospital fees and charges increased to HKD 705,153,000, up from HKD 662,217,000 in the same period last year, representing a growth of approximately 6.5%[24]. - Total revenue for the six months ended June 30, 2022, was HKD 732,685,000, with medical services contributing HKD 705,153,000, elderly care services HKD 27,151,000, and property development HKD 381,000[26]. - Revenue from inpatient medical services was HKD 251,820,000, outpatient medical services HKD 238,573,000, and other medical services HKD 5,689,000[26]. - The elderly care services generated revenue of HKD 13,919,000, while nutrition product sales contributed HKD 3,666,000[26]. - Property sales accounted for HKD 9,566,000, leading to a total of HKD 9,947,000 from property development[26]. - Revenue recognized at a point in time was HKD 708,036,000, while revenue recognized over time was HKD 24,649,000[26]. Assets and Liabilities - Non-current assets decreased to HKD 2,214,251 as of June 30, 2022, from HKD 2,507,443 as of December 31, 2021, indicating a decline of approximately 11.7%[8]. - Current liabilities amounted to HKD 1,300,720, a slight decrease from HKD 1,338,475 at the end of 2021[10]. - The total assets less current liabilities stood at HKD 2,042,056, a decrease from HKD 2,151,063 at the end of 2021[10]. - Total liabilities as of June 30, 2022, were HKD 1,689,909,000, with medical segment liabilities at HKD 1,132,518,000[49]. - The company’s current liabilities exceeded its current assets as of June 30, 2022, indicating potential liquidity issues[19]. - The total value of mortgaged assets as of June 30, 2022, was HKD 887,303,000, compared to HKD 882,295,000 as of December 31, 2021[87]. Operational Highlights - The company operates in three main segments: medical services, elderly care, and property development, all primarily in mainland China[40]. - The company established medical alliance agreements with Nanjing Mingzhou Rehabilitation Hospital and Southeast University Hospital to enhance cooperation in medical projects[107]. - The company is expanding its high-end comprehensive clinic services in Nanjing, with ongoing renovations to provide a wide range of medical services[107]. - The Kunming Hospital recorded a total of 171,452 outpatient visits, an increase from 134,820 visits in the previous year, and 8,520 inpatient admissions, up from 7,294 admissions[112]. - The Nanjing Hospital achieved 1,340,016 outpatient visits, significantly higher than 491,565 visits in the previous year, and 13,536 inpatient admissions, slightly down from 14,412 admissions[112]. Challenges and Future Outlook - The company continues to face significant uncertainty due to the ongoing economic conditions and the impact of the COVID-19 pandemic on demand for its services and products[21]. - The elderly care division anticipates continued operational impacts from the severe pandemic situation in the second half of 2022, with a focus on maintaining stable operations[146]. - The company expects ongoing volatility in the economic and business environment due to factors such as COVID-19 variants, geopolitical tensions, and rising interest rates[148]. - The company will maintain a prudent approach and continue to review and adjust its business and investment strategies to adapt to the challenging economic environment[148]. Shareholder Information - Major shareholders include Tongfang Co., Ltd. and Resuccess Investments Limited, each holding approximately 27.62% of the issued shares[156]. - The company’s executive Ms. Zhuang holds a total of 2,604,889,140 shares, representing approximately 17.99% of the issued ordinary shares[149]. - Major shareholders include Tianan China Investment Limited holding 1,857,529,625 shares, representing 12.82% of the issued ordinary shares[160]. - The total issued share capital of the company as of June 30, 2022, is 14,480,072,773 shares[160]. Governance and Compliance - The company has complied with the corporate governance code as per the listing rules during the six months ending June 30, 2022[166]. - The audit committee reviewed the accounting principles and practices adopted by the group, including the interim financial statements for the six months ending June 30, 2022[165]. - The board of directors confirmed compliance with the standard code of conduct for securities transactions during the six months ending June 30, 2022[167].

Financial Performance - The total revenue for the year ended December 31, 2021, was HKD 1,465,679,000, an increase from HKD 1,197,396,000 in 2020[9] - The company reported a loss attributable to owners of HKD 137,296,000 for the year, compared to a loss of HKD 111,928,000 in 2020, primarily due to increased impairment losses on financial assets of HKD 68,905,000[9] - The basic loss per share for the year was HKD 0.948, compared to HKD 0.773 in 2020[9] - The net asset value per share as of December 31, 2021, was HKD 0.117, down from HKD 0.123 in 2020[10] Medical Segment Performance - The medical segment generated revenue of HKD 1,372,032,000, up from HKD 1,093,752,000 in 2020, with a profit increase to HKD 59,573,000 from HKD 31,728,000[14] - The EBITDA for the medical segment was HKD 195,567,000, an increase from HKD 174,073,000 in 2020[14] - Nanjing Hospital recorded a total of 1,180,171 outpatient visits in 2021, up from 712,829 in 2020, and 27,154 inpatient admissions, slightly increasing from 27,062 in 2020[23] - Kunming Hospital achieved 299,951 outpatient visits in 2021, compared to 229,930 in 2020, and 15,917 inpatient admissions, up from 13,441 in 2020[23] Elderly Care Division - The elderly care division reported a revenue decline to HKD 79,889,000 in 2021 from HKD 82,392,000 in 2020, with losses increasing to HKD 72,135,000 from HKD 34,845,000[24] - The group provided home care services to 34 elderly individuals, with a total of 5,419 visits in 2021, down from 46 individuals and 7,143 visits in 2020[26] - The elderly care division aims to enhance marketing efforts to promote elderly care products and services, and will introduce home care services[62] Property and Investment Performance - As of December 31, 2021, the investment property portfolio of the group, which is 100% owned, includes serviced apartments with a total construction area of 25,804 square meters and retail shopping areas with a total construction area of 9,334 square meters, with a total book value of HKD 549,570,000, up from HKD 530,396,000 in 2020[28] - For the property development business, the group recorded revenue of HKD 6,803,000 in 2021, down from HKD 11,851,000 in 2020, but achieved a profit of HKD 439,000 compared to a loss of HKD 1,638,000 in the previous year[29] - The investment property segment generated rental income of HKD 4,756,000 in 2021, down from HKD 6,125,000 in 2020, while achieving a profit of HKD 6,296,000 compared to a loss of HKD 2,986,000 in 2020[30] Debt and Financial Position - The total borrowings of the group reached HKD 919,940,000 as of December 31, 2021, down from HKD 971,379,000 in 2020[43] - The group's debt ratio, calculated as net borrowings divided by total equity, was 16.5% as of December 31, 2021, compared to 17.9% in 2020[44] - The group recorded a full impairment loss provision of HKD 68,846,000 for the loan, significantly higher than HKD 22,468,000 in 2020[40] Corporate Governance - The company has a diverse board with members experienced in finance, law, and engineering, enhancing its governance and strategic direction[70] - The company is focused on expanding its market presence and enhancing operational efficiency through experienced leadership[71] - The board's composition reflects a commitment to corporate governance and strategic oversight in the healthcare sector[72] - The company has implemented measures to maintain high standards of corporate governance[123] Shareholder Information - As of December 31, 2021, the company had a total of 14,480,072,773 shares issued, with a significant shareholder, Vigor Online Offshore Limited, holding 2,592,514,140 shares, representing 17.90% of the total issued shares[96] - Major shareholders include Tongfang Co., Ltd. and Resuccess Investments Limited, each holding 4,000,000,000 shares, accounting for 27.62% of the total issued shares[101] - The company reported no final dividend for the year ended December 31, 2021, consistent with the previous year[86] Future Plans and Strategies - The company plans to continue expanding its operations despite the challenges posed by the COVID-19 pandemic[14] - In 2022, the medical division plans to cautiously implement the development of key strategic projects, including the second phase of Kunming Hospital and the Nuclear Medicine Center in Nanjing[60] - The company aims to achieve sustainable quality development and become a long-lasting sustainable enterprise[200] Community and Social Responsibility - The company has launched multiple public welfare projects, providing health checks and community services to share economic benefits with those in need[200] - The company is committed to a zero-tolerance policy towards unethical behavior and corruption, promoting a culture of integrity[199] - The company continues to engage with employees, patients, customers, and the community to combat the pandemic and encourage mutual support[200]

Financial Performance - The company reported unaudited revenue of HKD 708,672,000 for the six months ended June 30, 2021, representing a 50% increase from HKD 472,937,000 in the same period of 2020[2]. - Gross profit for the same period was HKD 136,563,000, up from HKD 87,301,000, indicating a gross margin improvement[2]. - The company incurred a loss before tax of HKD 59,721,000, an improvement from a loss of HKD 67,253,000 in the prior year[5]. - The net loss for the period was HKD 65,779,000, compared to a net loss of HKD 67,912,000 in the previous year, showing a slight reduction in losses[5]. - Total revenue for the six months ended June 30, 2021, was HKD 708,672,000, representing a 49.8% increase from HKD 472,937,000 in the same period of 2020[36]. - The group reported a net loss before tax of HKD 59.721 million for the six months ended June 30, 2021, compared to a loss of HKD 67.253 million for the same period in 2020[82]. - The company reported a total loss of HKD (73,899,000) for the six months ended June 30, 2021, compared to a loss of HKD (70,015,000) in the same period in 2020, indicating a 4.1% increase in losses[10][11]. Revenue Breakdown - Revenue from hospital fees and charges was HKD 662,217,000, up 53.0% from HKD 432,839,000 year-on-year[36]. - Revenue from elderly care-related services and nutritional product sales was HKD 19,497,000, a slight increase of 7.3% from HKD 18,165,000 in the previous year[36]. - Revenue from property development sales was HKD 6,074,000, significantly up from HKD 927,000 in the same period last year, marking a 553.0% increase[36]. - Revenue from medical services, including inpatient and outpatient services, accounted for HKD 258,520,000 and HKD 194,314,000 respectively, contributing to the overall medical revenue of HKD 662,217,000[40]. - The healthcare segment generated revenue of HKD 662,217,000 for the six months ended June 30, 2021, up from HKD 432,839,000 in the same period of 2020, with an EBITDA of HKD 93,539,000[156]. Assets and Liabilities - The company's total assets as of June 30, 2021, were HKD 2,240,739,000, down from HKD 2,297,450,000 at the end of 2020[14]. - Current liabilities increased to HKD 1,195,685,000 from HKD 1,127,724,000, reflecting a rise in operational obligations[14]. - The company’s equity attributable to owners decreased to HKD 1,721,164,000 from HKD 1,785,074,000, indicating a decline in shareholder equity[16]. - The group’s liabilities totaled HKD 1,675.135 million as of June 30, 2021, compared to HKD 1,624.540 million as of December 31, 2020[94]. - The total amount of trade receivables as of June 30, 2021, was HKD 201,732,000, a significant increase from HKD 136,301,000 as of December 31, 2020, reflecting a growth of 47.9%[14][15]. - The total outstanding loans as of June 30, 2021, were HKD 971,290,000, slightly down from HKD 971,379,000 as of December 31, 2020[133]. Cash Flow and Financing - For the six months ended June 30, 2021, the company reported a net cash inflow from operating activities of HKD 41,763,000, compared to a net outflow of HKD 107,137,000 in the same period of 2020[23]. - The company reported cash and cash equivalents of HKD 539,040,000, a decrease from HKD 616,474,000 at the end of 2020[14]. - New borrowings amounted to HKD 73,337,000, while repayments totaled HKD 81,089,000, resulting in a net cash outflow from financing activities of HKD 9,125,000[25]. - The company has access to a standby loan facility of HKD 300,000,000, which may provide additional liquidity if needed[28]. - The company’s total borrowings included HKD 216,234,000 in unsecured loans and HKD 228,131,000 in secured bank borrowings as of June 30, 2021[132]. Operational Highlights - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[2]. - The company is preparing for the certification assessment of a tertiary comprehensive hospital, with the application submitted in April 2021[158]. - Nanjing Hospital recorded a total of 491,565 outpatient visits, 14,412 inpatient admissions, and 28,546 examinations during the review period, representing increases from 293,876 outpatient visits, 11,989 inpatient admissions, and 15,472 examinations in 2020[161]. - The elderly care segment reported revenue of HKD 38,060,000, up from HKD 35,731,000 in 2020, but incurred a loss of HKD 11,492,000 compared to a loss of HKD 9,558,000 in the previous year[163]. - The company aims to enhance member satisfaction and service quality in its community village operations by integrating healthcare and elderly care services[164]. Investment and Capital Expenditures - The company’s investment in property, plant, and equipment amounted to HKD 70,780,000, up from HKD 41,658,000 in the previous year, reflecting ongoing capital expenditures[24]. - Capital expenditures for property, plant, and equipment amounted to HKD 37,590,000, while investment properties accounted for HKD 14,683,000 for the six months ended June 30, 2021[146]. - The group utilized HKD 153,994,000 for the purchase and improvement of medical and healthcare equipment[189]. Tax and Other Expenses - Tax expenses for the six months ended June 30, 2021, showed a significant increase in corporate income tax to HKD (6,109,000) from HKD (453,000) in 2020, reflecting a rise of 1247.9%[8][9]. - The company’s interest paid increased to HKD 29,930,000 from HKD 21,891,000 year-over-year, indicating rising financing costs[24]. - The group reported a foreign exchange loss of HKD 3.423 million for the six months ended June 30, 2021[97].

China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 * (於百慕達註冊成立之有限公司) (股份代號： 383) 2020 年 報 * · 中文名稱值供最別 中國醫療網絡有限公司 目錄 公司資料 2 主席報告 3 董事簡介 20 董事會報告 24 企業管治報告 32 環境、社會及管治報告 49 獨立核數師報告 62 綜合損益表 68 綜合損益表及其他全面收益表 69 綜合財務狀況報表 70 綜合權益變動表 72 綜合現金流量表 73 綜合財務報表附註 75 財務概要 185 1 二零二零年年報 中國醫療網絡有限公司 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 * (於百慕達註冊成立之有限公司) (股份代號： 383) | --- | --- | |----------|--------------------| | | | | | | | 2020 | | | 中期報告 | | | | | | | * 中文名稱劇的服务 | 中國醫療網絡有限公司 本集團未經審核之業績 中國醫療網絡有限公司（「本公司」）之董事會（分別為「董事」及「董事會」）謹此宣 佈，本公司及其附屬公司（「本集團」）截至二零二零年六月三十日止六個月之未經審 核綜合業績連同截至二零一九年度同期之比較數字如下：－ 簡明綜合損益表 截至二零二零年六月三十日止六個月 | --- | --- | --- | --- | |--------------------------------|-------|------------------------------------|---------------------------------------------------------| ...

Financial Performance - For the eighteen months ending December 31, 2019, the group recorded a revenue decline of HKD 2,042,090,000, compared to HKD 2,318,159,000 in 2018, with a profit attributable to shareholders of HKD 2,176,000, recovering from a loss of HKD 137,110,000 in the previous fiscal year[8]. - The healthcare segment generated revenue of HKD 1,622,141,000, up from HKD 964,563,000 in 2018, with a profit of HKD 35,733,000 compared to HKD 5,226,000 in 2018[14]. - EBITDA for the healthcare segment was HKD 239,760,000, an increase from HKD 130,387,000 in 2018[14]. - The company did not recommend a final dividend for the eighteen months ending December 31, 2019, consistent with no dividend in 2018[10]. - The revenue from the elderly care business reached HKD 150,272,000, an increase from HKD 100,753,000 in the previous year, with a reduced loss of HKD 44,322,000 compared to HKD 58,154,000[19]. - The property development segment recorded a revenue decrease of HKD 7,326,000, with a loss of HKD 5,031,000 compared to a profit of HKD 917,000 in the previous year[23]. - Rental income from investment properties was HKD 9,266,000, an increase from HKD 7,358,000, while profit decreased to HKD 15,434,000 from HKD 23,621,000[24]. - The securities trading and investment segment saw a revenue drop to HKD 202,119,000 from HKD 1,224,445,000, but profit increased to HKD 14,474,000 from a loss of HKD 24,366,000[25]. - The company implemented cost reduction and restructuring measures to improve financial performance starting from the second half of 2018[19]. - The group recorded interest income from lending activities of HKD 50,966,000 in 2019, significantly up from HKD 2,308,000 in 2018, with a profit of HKD 46,669,000 compared to HKD 2,247,000 in the previous year[31]. Healthcare Services - The Nanjing Hospital, the flagship facility, currently operates 39 clinical departments and plans to increase its bed capacity to 1,200 following renovations[15]. - The Nanjing Hospital has established a stroke center and has been included in the second batch of municipal chest pain and trauma centers to enhance emergency services[15]. - Kunming Hospital currently operates 30 clinical medical technology departments and has recruited renowned experts from other top-tier hospitals[16]. - Nanjing Hospital recorded 1,236,573 outpatient visits, 43,384 inpatient admissions, and 75,869 health check-ups, while Kunming Hospital had 334,678 outpatient visits, 20,634 inpatient admissions, and 113,008 health check-ups[16]. - The group is focused on expanding its healthcare services and enhancing its operational efficiency through strategic investments and management improvements[12]. - Nanjing Hospital plans to enhance talent development and improve medical technology and service innovation capabilities in 2020[49]. - Kunming Hospital aims to maintain stable business growth and improve overall medical quality while developing a modern nuclear medicine center[51]. Financial Position and Assets - As of December 31, 2019, the group's total borrowings reached HKD 793,363,000, a decrease from HKD 825,503,000 in 2018[33]. - The group's non-current assets amounted to HKD 2,222,623,000 as of December 31, 2019, slightly down from HKD 2,285,771,000 in 2018[32]. - The debt ratio calculated based on net borrowings to total equity was 7.5% as of December 31, 2019, down from 13.8% in 2018[35]. - The group's investment portfolio performance is generally influenced by global and regional economic, political, and financial market conditions[30]. - The group's total assets included investment properties valued at HKD 772,520,000 as of December 31, 2019[32]. - The investment property portfolio's total book value was HKD 512,000,000, down from HKD 524,376,000 in the previous year[21]. Corporate Governance - The company has a strong board with members holding significant experience in finance and management across various sectors, enhancing its strategic decision-making capabilities[65][66]. - The board includes independent directors with extensive backgrounds in finance and engineering, ensuring diverse perspectives in governance[70][71]. - The company has implemented measures to maintain high standards of corporate governance, which is considered crucial for enhancing shareholder value[111]. - The board consists of 11 members, including 4 executive directors, 3 non-executive directors, and 4 independent non-executive directors[112]. - The company has established governance functions to assist the board in monitoring management's business activities[146]. - The company has adopted a board diversity policy to enhance sustainable and balanced development, considering factors such as gender, age, and professional experience[145]. - The company has arranged training for new directors to ensure they understand their roles and responsibilities under regulatory requirements[119]. - The company has established a comprehensive internal control system with a clear organizational structure and defined responsibilities to ensure effective checks and balances[172]. Environmental Management - The company is committed to reducing the adverse impact of its operations on the natural environment and adheres to relevant environmental laws and regulations[198]. - The company has not reported any serious violations of environmental laws and regulations during the reporting period[198]. - The medical wastewater generated by the group’s hospitals during the period was 339,470 cubic meters, an increase from 237,047 cubic meters in 2018[199]. - The group has implemented three key principles for wastewater treatment: on-site treatment, integrated compliance and risk management, and ecological safety[200]. - The hospitals are equipped with efficient wastewater treatment systems that comply with the national wastewater discharge standards (GB8978-1996) at the tertiary level[200]. - Additional biochemical treatment processes have been added to upgrade the system and enhance environmental standards for wastewater discharge[200]. - Real-time monitoring equipment has been installed in the wastewater treatment system to ensure operational effectiveness and compliance with regulatory requirements[200]. Future Outlook - The group anticipates a challenging operating environment due to the impact of COVID-19 but remains optimistic about the long-term prospects of the private healthcare and elderly care sectors in China[48]. - The company is in discussions with the borrower regarding the total debt repayment and is monitoring the repayment progress closely[56]. - The company will maintain a prudent approach in light of global economic uncertainties, including the impact of COVID-19 and geopolitical tensions, while seeking investment opportunities in China, Hong Kong, and the Asia-Pacific region[57]. - Future outlook includes a focus on sustainable growth and innovation to meet evolving market demands[69].

China Medical & HealthCare Group Limited 中 國 醫 療 網 絡 有 限 公 司 ˚ (於百ङ建註冊成立之有限公司) (股份代號： 383) 二零一九年 第二份中期報告 中文名詞庫的藏宗 中國醫療網絡有限公司 本集團未經審核之業績 中國醫療網絡有限公司（「本公司」）之董事會（分別為「董事」及「董事會」）謹此宣 佈，本公司及其附屬公司（「本集團」）截至二零一九年六月三十日止十二個月之未經 審核綜合業績連同截至二零一八年度同期之比較數字如下：－ 簡明綜合損益表 截至二零一九年六月三十日止十二個月 | --- | --- | --- | --- | |--------------------------------|-------|-----------------------------------------------------------------|--------------------------------| | | 附註 | 截至六月三十日止十二個月 \n二零一九年 千港元 \n（未經審核） | 二零一八年 千港元 \n（經審核） | | 收入 | 3 | ...

Financial Performance - Revenue for the six months ended December 31, 2018, was HKD 594,156,000, an increase of 6.9% compared to HKD 555,593,000 for the same period in 2017[2] - Gross profit for the same period was HKD 124,032,000, up from HKD 98,109,000, reflecting a significant improvement in profitability[4] - The company reported a profit of HKD 22,166,000 for the six months ended December 31, 2018, compared to a loss of HKD 69,122,000 in the prior year[6] - Basic and diluted earnings per share for the period were HKD 0.16, a recovery from a loss of HKD 0.43 per share in the previous year[4] - The company reported a loss before tax of HKD 30,250,000 for the period[93] - For the six months ended December 31, 2018, the company reported a profit of HKD 22,725,000, compared to a loss of HKD 62,544,000 for the same period in 2017[116] Assets and Liabilities - Total assets as of December 31, 2018, were HKD 2,215,139,000, a decrease from HKD 2,285,771,000 as of June 30, 2018[8] - Current liabilities decreased to HKD 1,030,297,000 from HKD 1,126,368,000, indicating improved liquidity management[10] - The company’s cash and cash equivalents stood at HKD 367,696,000, down from HKD 544,092,000, reflecting a tighter cash position[10] - Non-current assets totaled HKD 1,184,842,000, slightly down from HKD 1,207,359,000, indicating stability in long-term investments[8] - The total assets of the group amounted to HKD 3,356,480,000 as of December 31, 2018[106] - The group’s liabilities totaled HKD 1,552,271,000 at the end of the reporting period[106] - The company reported total borrowings of HKD 845,029,000 as of December 31, 2018, an increase from HKD 825,503,000 as of June 30, 2018[140] - The total borrowings of the group decreased to HKD 845,029,000 from HKD 1,510,774,000 in 2017, representing a reduction of approximately 44%[189] Cash Flow and Financing - For the six months ended December 31, 2018, the company reported a net cash outflow from operating activities of HKD 87,628,000, compared to a net inflow of HKD 180,536,000 in the same period of 2017[16] - The company incurred a cash outflow of HKD 69,067,000 from investing activities, a significant decrease from the inflow of HKD 122,371,000 in the previous year[18] - New borrowings amounted to HKD 236,843,000, while repayments totaled HKD 190,573,000, resulting in a net cash outflow from financing activities of HKD 14,353,000[18] - The company’s financing costs decreased significantly to HKD 25,717,000 from HKD 48,182,000, suggesting improved debt management[2] - The company’s total liabilities decreased significantly, reflecting improved financial health and management of debts[6] Revenue Recognition and Accounting Standards - The company has adopted new and revised Hong Kong Financial Reporting Standards, which may impact the presentation of financial results going forward[21] - The company has adopted Hong Kong Financial Reporting Standard 15, which has led to significant changes in accounting policies regarding revenue recognition[28] - Revenue from medical and elderly care services is recognized over time as the services are provided, reflecting the control transfer to customers[35] - Revenue from pharmaceutical sales is recognized at the point when control of the goods is transferred to the customer[36] - The revenue recognition process involves identifying contracts with customers and determining performance obligations[28] - The company has chosen to apply HKFRS 15 retrospectively only to contracts that were not completed as of July 1, 2018[28] Segment Performance - The healthcare segment generated a profit of HKD 8,748,000, while the elderly care segment reported a loss of HKD 10,786,000[93] - The company’s property development segment recorded revenue of HKD 1,287,000[84] - The group’s financial services segment generated revenue of HKD 12,304,000[93] - The elderly care segment reported revenue of HKD 62,602,000, up from HKD 53,896,000 in 2017, but incurred a loss of HKD 10,786,000 compared to a loss of HKD 18,122,000 in the previous year[173] - The company implemented restructuring measures in the healthcare segment to reduce operating expenses and streamline management[170] Future Outlook and Strategic Plans - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[6] - The company is focused on expanding its operations in mainland China, particularly in healthcare and elderly care sectors[25] - The group believes the outlook for China's private healthcare and elderly care industry is optimistic due to favorable demographic and macroeconomic factors, along with government support policies[200] Employee and Operational Metrics - The group employed 2,321 employees as of December 31, 2018, an increase from 2,212 employees in 2017, reflecting a growth in workforce[199] - The number of outpatient visits at Nanjing Hospital increased to 390,187 from 385,543 in 2017, while inpatient admissions rose to 13,746 from 13,264[171] - The company plans to increase inpatient capacity at Nanjing Hospital by 400 beds following the operation of a new building at the end of 2018[171] Investment and Capital Expenditures - The company made capital expenditures of HKD 42,089,000 for the purchase of property, plant, and equipment, up from HKD 31,071,000 in the prior year[18] - The company has capital commitments of HKD 208,261,000 as of December 31, 2018, compared to HKD 215,191,000 on June 30, 2018[154] - Approximately HKD 600,000,000 from the share subscription proceeds is expected to be used for working capital and expanding the group's hospital and healthcare business[192]